TT
Tempest Therapeutics, Inc.
SEC filingBiotechnology · Brisbane, CA
Amount raised$4.1Msold at filing
Total offering$4.1M
Investors in the raise1count reported to the SEC
FiledJun 23, 2026first sale May 29, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
John David YeeDirector
Matthew AngelExecutive Officer, Director
Justin TrojanowskiExecutive Officer
William Drake RicheyDirector
Executive officers, directors and promoters as listed on the Form D.